Tempus AI, Inc. is a technology company. The Company provides next generation diagnostics across multiple disease areas, with technology capabilities, harnessing the data and analytics to help personalize medicine. The Company’s product lines include genomics, data, and artificial intelligence applications (AI). Its genomics product line leverages its laboratories to provide next generation sequencing, diagnostics, polymerase chain reaction (PCR), profiling, molecular genotyping, and other anatomic and molecular pathology testing. The Company's AI applications are focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools. Its primary product of AI applications is Next, an AI platform that leverages machine learning to apply an intelligent layer onto routinely generated data to proactively identify and minimize care gaps for oncology and cardiology patients.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 116.24% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 693.40M.
Overvalued
The company’s latest PE is 41.45, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 74.63M shares, increasing 2.48% quarter-over-quarter.
Held by Catherine Wood
Star Investor Catherine Wood holds 7.42M shares of this stock.